Mankind Pharma Ltd

- The company has a scheduled repayment of Rs. 2,000 crores acquisition-related debt in FY'26, with Rs. 500 crores repaid in Q1 and the remaining Rs. 1,500 crores targeted for repayment by October 2025. - Interest cost on acquisition debt for the year is expected to be Rs. 450-475 crores. - The company aims to clear all debt by FY'28, indicating no immediate plans for new debt fundraising. - CAPEX guidance of around 5% of revenue for FY'26 includes Rs. 150-200 crore spent on the biosimilar facility; no separate fundraising indicated for this. - There is no mention of any planned equity fundraising in the provided transcript. - Overall, the focus is on reducing existing debt rather than raising new funds through debt or equity in the near term.

- Mankind Pharma is investing in a new biologic/biosimilar facility at Baroda, aimed at scaling up and de-risking operations from their Ambernath site (BSV facility). - The Capex for Phase 1 of this biologic facility is estimated around Rs. 150 to Rs. 200 crore, expected to be completed by the end of the next calendar year. - Approximately Rs. 100 crore of this Capex is anticipated as cash outflow in FY26. - This Capex includes all biologic products of BSV, including Anti-D and Anti-ID. - The biologic facility development is planned in two phases: first for drug substance and second for drug products. - Mankind is also expanding its biological R&D facilities to strengthen innovation capabilities. - The Baroda facility is part of a risk mitigation strategy for BSV Ambernath and will enable entry into semi-regulated and stringent international markets. - The Capex for the biologic facility is included in the company's overall guidance of capital expenditure at around 5% of revenue for FY26.

- BSV (Biosimilars) is expected to grow at around 18%-20% overall in the coming year, with sequential quarterly improvement (Q2 > Q1, Q3 > Q2). - International business growth for BSV is expected to be upwards of 20%, supported by market penetrations like Russia and newer markets. - Domestic BSV growth is driven by both Rx and specialty segments (e.g., fertility drugs with 10-35%+ growth, anti-snake venom with high double-digit growth). - Mankind's domestic business organic growth is at 10% year-on-year, with overall company growth (including BSV) at 24.5%. - Modern trade and e-commerce channels in the OTC segment grew ~50% YoY, with channel share increasing to 11%. - Base business is seeing front-loaded expenses but is expected to deliver operating leverage and margin improvements going forward. - Expansion of biological facilities and R&D investments will support scaling and future innovation-led growth.

- Profit After Tax (PAT) declined 17.4% YoY in Q1 FY26 due to higher finance and depreciation costs linked to BSV consolidation. However, cash EPS slightly improved to Rs. 15.9 from Rs. 15.8 YoY. - Management aims to clear all acquisition-related debt by FY28, which should gradually reduce interest burden and improve PAT going forward. - Operating margin guidance remains stable with an EBITDA margin targeted at 25%-26% for the full fiscal year. - Gross margins expected to stay above 70%, supporting profitability. - BSV segment expected to grow 18%-20% with improving margins (26%-28%) from corrective actions and international business growth. - Base business operating margins are better than BSV currently, and expense front-loading suggests operating leverage and margin expansion in upcoming quarters. - Long-term focus on reducing debt, optimizing expense structure, and scaling high-growth biosimilars and consumer health segments to drive profit improvement.

The transcript provided from the Mankind Pharma Q1 FY26 earnings call does not explicitly mention the current or expected order book or pending orders. However, relevant operational and growth updates include: - BSV business expected to grow 18%-20% with increasing traction internationally and in specialty segments. - Ongoing international product registrations and approvals, including recent board approval for Russia. - New biological facility at Ambernath under construction to scale up and de-risk BSV operations, with Capex around Rs. 150-200 crores expected by end of calendar year 2026. - Expansion in R&D and manufacturing capacities to support pipeline and export markets, including Dydrogesterone facility running at ~60% capacity, expected to increase as approvals arrive. - Strong order flow reflected in organic domestic business growth of 10% and overall revenue growth of 24.5% YoY, partly driven by BSV consolidation. - Inventory and working capital efficiencies improving, with cash flow from operations up 54% YoY. No specific numerical data on order book or pending orders was disclosed.